What's behind Abbott Laboratories' latest stock pullback?

Traders Union
All News
Financial News
Abbott Laboratories slides 1.65% today

Highlights

Abbott Laboratories sustained earnings momentum with consistent revenue growth across business segments, extending its 55-year streak of rising dividends at a 2.5% yield.
The company is probing recent cyberattack and data theft allegations, though its share price remains pressured in a broader selloff.
Technical signals reflect short- and medium-term bullish momentum against a bearish long-term backdrop, with a five-day trading range forecast of $92.57 to $107.39 and a 74% chance of an upward move.

Dividend streak and earnings growth as sentiment is tempered by hacks

Abbott Laboratories reported ongoing positive earnings momentum, supported by steady revenue and profit growth in its diversified businesses. The company continued its 55-year streak of consecutive dividend increases, with the current yield around 2.5%. Abbott is also investigating recent claims of cyberattacks and data theft, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, observes that Abbott’s technical position looks fragile beneath the 200-day average despite recent support at shorter moving averages. He notes overbought momentum and a sharp intraday retreat, while the persistent news of cyberattack investigations and broader market selling raises caution on sentiment. Kharitonov points to the 55-year dividend streak as a stabilizer, but he questions the sustainability of current valuations given headline risks. He sees bullish intraday signals clashing with technical and sentiment headwinds. "Traders should beware: overbought momentum plus negative news flow often lead to sharp reversals in stocks trading below long-term averages."

Viktoras Karapetjanc, expert at Traders Union, sees Abbott’s fundamentals as strong thanks to robust earnings and a 55-year record of dividend hikes. He notes the diversified business model continues to deliver, and the stock’s short- to medium-term bullish structure remains intact above key moving averages. Karapetjanc expects further growth opportunities as positive momentum outweighs short-term pressure, with a 74% likelihood of upward movement in the coming sessions. "With the company’s resilience and ongoing profit momentum, investors should look for a breakout above $101.77 to unlock the next leg higher."

Jainam Mehta, market strategist, believes Abbott’s current retreat tests immediate support while technical indicators reveal an overbought condition. He notes that the contradiction between strong intraday momentum and price weakness may offer tactical swing trade setups around $99.91 and $101.77. Mehta also highlights the asymmetric forecast, favoring upside but not ruling out a corrective dip if support breaks. "Traders might consider fading the overbought sentiment or watch for a potential breakout above resistance for quick momentum plays."

Bullish short-term momentum as long-term trend remains under pressure

Abbott is trading above both its 20-day and 50-day moving averages, listed at $93.67 and $89.96, indicating a firm short- and medium-term bullish trend. However, the stock remains below its 200-day moving average at $109.67, confirming that long-term momentum still faces bearish alignment, with immediate support and resistance marked by $99.91 and $101.77 respectively. Momentum readings are strong, with the Moving Average Convergence Divergence (MACD) signaling buy and the Average Directional Index (ADX) in a neutral zone, indicating trend strength is moderate. The Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) all identify overbought conditions, and Bull/Bear Power (BBP) shows buyers dominate intraday momentum while also flagging an overbought scenario. The Awesome Oscillator also supports the bullish intraday tone. The stock has retreated to $99.98, down 1.65% on the session after a downside gap of approximately $1.02 at the open, currently trading near today's low in a session marked by 1.86% intraday volatility. The close proximity to intraday support and mild volatility suggests pressure after the open, with short-term momentum readings slightly contradicting this intraday weakness.

Earlier, analysts noted that Abbott Laboratories demonstrated short- and medium-term strength but faced persistent long-term resistance, with overbought signals raising caution about upside potential. The current setup confirms the ongoing bullish momentum within a consolidating range while highlighting that a decisive move above $101.77 or below $99.91 may define the next direction for traders to monitor.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.